Terms: = Thyroid cancer AND CDKN2C, P42773, 1031, ENSG00000123080, INK4C, p18, p18-INK4C AND Treatment
9 results:
1. All-Cause and Cause-Specific Mortality Among Low-Risk Differentiated thyroid cancer Survivors in the United States.
Tran TV; Schonfeld SJ; Pasqual E; Haymart MR; Morton LM; Kitahara CM
Thyroid; 2024 Feb; 34(2):215-224. PubMed ID: 38149602
[No Abstract] [Full Text] [Related]
2. Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study.
Kawaguchi H; Yamamoto Y; Saji S; Masuda N; Nakayama T; Aogi K; Anan K; Ohtani S; Sato N; Takano T; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita T; Yotsumoto D; Toi M; Ohno S
Jpn J Clin Oncol; 2023 Mar; 53(3):203-211. PubMed ID: 36484305
[TBL] [Abstract] [Full Text] [Related]
3. Assessing the prognostic value of stemness-related genes in breast cancer patients.
Wang WJ; Wang H; Wang MS; Huang YQ; Ma YY; Qi J; Shi JP; Li W
Sci Rep; 2020 Oct; 10(1):18325. PubMed ID: 33110086
[TBL] [Abstract] [Full Text] [Related]
4. Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (cdkn2c) loss assay in sporadic medullary thyroid carcinoma.
Maxwell JE; Gule-Monroe MK; Subbiah V; Hu M; Perrier ND; Cabanillas ME; Lee JE; Graham PH; Cote GJ; Busaidy NL; Grubbs EG
Surgery; 2020 Jan; 167(1):80-86. PubMed ID: 31648931
[TBL] [Abstract] [Full Text] [Related]
5. Clinical analysis of cervical lymph node metastasis risk factors in patients with papillary thyroid microcarcinoma.
Luo Y; Zhao Y; Chen K; Shen J; Shi J; Lu S; Lei J; Li Z; Luo D
J Endocrinol Invest; 2019 Feb; 42(2):227-236. PubMed ID: 29876836
[TBL] [Abstract] [Full Text] [Related]
6. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.
Demeure MJ; Aziz M; Rosenberg R; Gurley SD; Bussey KJ; Carpten JD
World J Surg; 2014 Jun; 38(6):1296-305. PubMed ID: 24633422
[TBL] [Abstract] [Full Text] [Related]
7. Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas.
Pita JM; Figueiredo IF; Moura MM; Leite V; Cavaco BM
J Clin Endocrinol Metab; 2014 Mar; 99(3):E497-507. PubMed ID: 24423316
[TBL] [Abstract] [Full Text] [Related]
8. Medullary thyroid carcinoma: long-term outcomes of surgical treatment.
Abraham DT; Low TH; Messina M; Jackson N; Gill A; Chou AS; Delbridge L; Learoyd D; Robinson BG; Sidhu S; Sywak M
Ann Surg Oncol; 2011 Jan; 18(1):219-25. PubMed ID: 20878247
[TBL] [Abstract] [Full Text] [Related]
9. Value of the cervical compartments in the surgical treatment of papillary thyroid carcinoma.
Goropoulos A; Karamoshos K; Christodoulou A; Ntitsias T; Paulou K; Samaras A; Xirou P; Efstratiou I
World J Surg; 2004 Dec; 28(12):1275-81. PubMed ID: 15517478
[TBL] [Abstract] [Full Text] [Related]
